Zomedica (ZOM) 10-Q 8 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 08, 2019
Document Information [Line Items]
Entity Registrant Name	Zomedica Pharmaceuticals Corp.
Entity Central Index Key	0001684144
Trading Symbol	zom
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		108,038,398
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Unaudited Interim Con

Condensed Unaudited Interim Consolidated Balance Sheet - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 5,822,148	$ 1,940,265
Prepaid expenses and deposits	1,389,176	1,867,034
Trade and other receivable	95,550	53,659
	7,306,874	3,860,958
Prepaid expenses and deposits	7,300	1,442,415
Property and equipment	794,364	717,088
Right-of-use asset	1,358,348
Intangible assets	12,521	13,058
	9,479,407	6,033,519
Current liabilities:
Accounts payable and accrued liabilities	1,796,803	2,376,519
	1,796,803	2,376,519
Shareholders' equity:
Series 1 preferred shares, without par value; 20 shares authorized (2018 - nil) Issued and outstanding 12 series 1 preferred shares (2018 - nil)	11,962,811
Capital stock Authorized Unlimited common shares without par value Issued and outstanding 108,038,398 common shares (2018 - 97,598,898)	38,647,822	30,410,648
Common stock subscribed		4,280,000
Additional paid-in capital	3,427,095	1,240,139
Accumulated deficit	(46,355,124)	(32,273,787)
	7,682,604	3,657,000
	$ 9,479,407	$ 6,033,519

Condensed Unaudited Interim C_2

Condensed Unaudited Interim Consolidated Balance Sheet (Parentheticals) - $ / shares $ / shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	20	0
Preferred stock, shares issued (in shares)	12	0
Preferred stock, shares outstanding (in shares)	12	0
Capital stock, unlimited common shares authorized	Unlimited	Unlimited
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, shares issued (in shares)	108,038,398	97,598,898
Capital stock, shares outstanding (in shares)	108,038,398	97,598,898

Condensed Unaudited Interim C_3

Condensed Unaudited Interim Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Expenses:
Research and development	$ 1,061,507	$ 2,534,620	$ 8,592,882	$ 3,134,961
General and administrative	921,446	1,248,490	4,152,709	2,408,662
Professional fees	211,520	336,455	950,914	708,402
Amortization - right-of-use asset	127,345		254,690
Amortization - intangible asset	270	693	537	1,379
Depreciation	68,925	27,459	130,979	64,158
Loss from operations	2,391,013	4,147,717	14,082,711	6,317,562
Loss on fixed assets	1,308		1,308
Interest expense	12,164		18,338
Gain on settlement of liabilities			(19,737)
Foreign exchange gain	(58)	(3,319)	(1,283)	(1,835)
Loss before income taxes	2,404,427	4,144,398	14,081,337	6,315,727
Income tax expense
Net loss and comprehensive loss	$ 2,404,427	$ 4,144,398	$ 14,081,337	$ 6,315,727
Weighted average number of common shares - basic and diluted (in shares)	108,038,398	92,527,470	104,528,705	91,527,862
Loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.04)	$ (0.13)	$ (0.07)

Condensed Unaudited Interim C_4

Condensed Unaudited Interim Consolidated Statements of Shareholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]		Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017		90,225,869
Balance at Dec. 31, 2017		$ 18,244,659			$ 1,768,526	$ (15,626,100)	$ 4,387,085
Stock issuance for services (in shares)		641,717					641,717
Stock issuance for services		$ 1,238,513					$ 1,238,513
Stock issued from financing, number (in shares)		1,861,627
Stock issuance for financing, net of costs		$ 3,978,690					3,978,690
Stock-based compensation					7,288		$ 7,288
Stock issued due to exercise of options (in shares)		1,781,996					1,781,996
Stock issued due to exercise of options		$ 1,796,262			(357,954)		$ 1,438,308
Net loss						(6,315,727)	(6,315,727)
Balance (in shares) at Jun. 30, 2018		94,511,209
Balance at Jun. 30, 2018		$ 25,258,124			1,417,860	(21,941,827)	4,734,157
Balance (in shares) at Dec. 31, 2018		97,598,898
Balance at Dec. 31, 2018		$ 30,410,648		4,280,000	1,240,139	(32,273,787)	3,657,000
Stock issuance for services (in shares)		707,236	[1],[2]
Stock issuance for services		$ 792,104	[1],[2]				792,104
Stock issued from financing, number (in shares)	12	9,337,529
Stock issuance for financing, net of costs	$ 11,962,811	$ 6,690,922	[3],[4]	(4,280,000)			14,373,733
Stock-based compensation					2,341,104		$ 2,341,104
Stock issued due to exercise of options (in shares)		394,735					394,735
Stock issued due to exercise of options		$ 754,148			(154,148)		$ 600,000
Net loss						(14,081,337)	(14,081,337)
Balance (in shares) at Jun. 30, 2019	12	108,038,398
Balance at Jun. 30, 2019	$ 11,962,811	$ 38,647,822			$ 3,427,095	$ (46,355,124)	$ 7,682,604
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance;
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities;
[3]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018.The Company recorded $465 of share issuance costs as an offset to common stock;
[4]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded $592,707 of share issuance costs as an offset to common stock in the three month period ended March 31, 2019. A decrease of $4,094 in share issuance costs was recorded as an offset to common stock in the three month period ended June 30, 2019.

Condensed Unaudited Interim C_5

Condensed Unaudited Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Cash flows used in operating activities:
Net loss for the period	$ (2,404,427)	$ (4,144,398)	$ (14,081,337)	$ (6,315,727)
Adjustments for
Depreciation	(68,925)	(27,459)	(130,979)	(64,158)
Amortization - intangible asset	270	693	537	1,379
Amortization - right-of-use asset	127,345		254,690
Loss on fixed assets	1,308		1,308
Stock issued for services		1,238,513	792,104	1,238,513
Stock-based compensation		1,597	2,341,104	7,288
Change in non-cash operating working capital
Trade and other receivable	(17,578)	19,754	(41,891)	(21,355)
Prepaid expenses	92,418	(241,270)	263,010	(247,764)
Deposits	(327,138)	(60,320)	(98,075)	(29,846)
Accounts payable and accrued liabilities	(5,977,134)	417,477	(579,716)	855,065
	(8,436,011)	(2,740,495)	(11,017,287)	(4,448,289)
Cash flows from financing activities:
Cash proceeds from financing of preferred shares	12,000,000		12,000,000
Cash proceeds from financing of common shares		4,002,496	3,000,000	4,002,496
Cash received from stock option exercises	0	30,522	600,000	1,438,308
Cash paid on stock issuance costs	(33,095)	(23,806)	(626,267)	(23,806)
	11,966,905	4,009,212	14,973,733	5,416,998
Cash flows used in investing activities:
Investment in property and equipment	(5,477)	(124,474)	(74,563)	(137,693)
	(5,477)	(124,474)	(74,563)	(137,693)
Increase in cash and cash equivalents	3,525,417	1,144,243	3,881,883	831,016
Cash and cash equivalents, beginning of period	2,296,731	3,134,920	1,940,265	3,448,147
Cash and cash equivalents, end of period	5,822,148	4,279,163	5,822,148	4,279,163
Supplemental cash flow information:
Interest paid	$ 12,164		$ 18,338

Note 1 - Nature of Operations a

Note 1 - Nature of Operations and Going Concern	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	1. Zomedica Pharmaceuticals Corp. ("Zomedica" or the “Company”) was incorporated on January 7, 2013 Business Corporations Act 2.4 May 14, 2015 On April 21, 2016, three 9674128 one 2.5 2.4 Capital Pool Companies May 2, 2016. June 21, 2016, Zomedica has one 100 190, 48108 1250, 639 5th T2P 0M9. On November 20, 2017, 1 November 21, 2017, Going concern The consolidated financial statements are prepared on a going concern basis, which assumes that the Company will be able to meet its obligations and continue its operations for the next twelve $46,355,124 June 30, 2019 ( December 31, 2018 - $32,273,787 no In order for the Company to continue as a going concern and fund any significant expansion of its operation or R&D activities, the Company will require significant additional capital. The Company’s ultimate success will depend on whether its future product candidates receive the necessary regulatory approval and it is able to successfully market approved products. The Company cannot be certain that it will be able to receive regulatory approval for any of its future product candidates, or that it will reach the level of sales and revenues necessary to achieve and sustain profitability. The availability of equity or debt financing will be affected by, among other things, the results of the Company’s research and development, its ability to obtain regulatory approvals, the market acceptance of its products, the state of the capital markets generally, strategic alliance agreements, and other relevant commercial considerations. In addition, if the Company raises additional funds by issuing equity securities, its then existing security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations and could require the Company to agree to operating and financial covenants that would restrict its operations. Any failure on its part to raise additional funds on terms favorable to the Company or at all, may not

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of preparation The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements. Basis of consolidation These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc. All inter-company accounts and transactions have been eliminated on consolidation.

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant accounting policies Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; deferred income taxes and forecasting future cash flows for assessing the going concern assumption. Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted. Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements. Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss. Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not three six June 30, 2019 Comprehensive loss The Company follows ASC topic 220. no Recently adopted accounting pronouncements In February 2016, No. 2016 02, 842 12 842 December 15, 2018. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. The Company adopted the new standard with an initial application date of January 1, 2019 not not January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permits the Company not not not

Note 4 - Critical Accounting Ju

Note 4 - Critical Accounting Judgments and Key Sources of Estimation Uncertainty	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Critical Accounting Judgments and Key Sources of Estimation Uncertainly [Text Block]	4. Critical accounting judgments and key sources of estimation uncertainty The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not may The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Critical areas of estimation and judgements in applying accounting policies include the following: Going concern These condensed unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP on a going concern basis, which assumes the realization of assets and discharge of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company’s ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy their obligations as they become due. Stock-based payments The Company estimates the fair value of convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around assumptions and inputs such as expected term to maturity, expected volatility and expected dividends. Useful lives of property and equipment The Company reviews the estimated useful lives of property and equipment with definite useful lives at the end of each year and assesses whether the useful lives of certain items should be shortened or extended, due to various factors including technology, competition and revised service offerings. During the three six June 30, 2019, not may not Deferred income taxes The calculation of deferred income taxes is based on assumptions which are subject to uncertainty as to timing and which tax rates are expected to apply when temporary differences reverse. Deferred tax recorded is also subject to uncertainty regarding the magnitude of non-capital losses available for carry forward and of the balances in various tax pools. By their nature, these estimates are subject to measurement uncertainty, and the effect on the financial statements from changes in such estimates in future period could be material. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets are reviewed at each balance sheet date and adjusted to the extent that it is no

Note 5 - Prepaid Expenses and D

Note 5 - Prepaid Expenses and Deposits	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Prepaid Rent [Text Block]	5. Prepaid expenses and deposits June 30, December 31, 2019 2018 Prepaid rent (i) $ - $ 1,613,038 Deposits (ii) 1,224,180 1,596,104 Prepaid FDA fees 62,995 - Prepaid marketing (iii) 41,218 37,465 Prepaid insurance (iii) 780 33,372 Other (iv) 67,303 29,470 Total $ 1,396,476 $ 3,309,449 (i) On July 31, 2018, 18,640 $1,269,073. January 1, 2019 $1,613,038. 842, December 31, 2018, $509,380 (ii) Deposits include payments made to vendors in advance and are primarily associated with research activity, design fees for additional office space, and equipment purchases. As of June 30, 2019 December 31, 2018, $1,389,176 $1,867,034 (iii) As of June 30, 2019 December 31, 2018, (iv) Other is comprised of subscription payments and software licensing. As of June 30, 2019 December 31, 2018,

Note 6 - Property and Equipment

Note 6 - Property and Equipment	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2017 $ 151,155 $ 76,058 $ 245,729 $ 36,957 $ 509,899 Additions 18,847 105,821 246,375 256,954 627,997 Disposals - - (139,467 ) (10,936 ) (150,403 ) Balance at December 31, 2018 170,002 181,879 352,637 282,975 987,493 Additions 137,126 3,414 3,350 65,673 209,563 Disposals (2,210 ) - - - (2,210 ) Balance at June 30, 2019 304,918 185,293 355,987 348,648 1,194,846 Accumulated depreciation Balance at December 31, 2017 42,802 11,845 74,875 9,220 138,742 Depreciation 62,116 17,740 86,368 37,460 203,684 Disposals - - (61,547 ) (10,474 ) (72,021 ) Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 38,683 13,153 33,785 45,358 130,979 Disposals (902 ) - - - (902 ) Balance at June 30, 2019 142,699 42,738 133,481 81,564 400,482 Net book value as at: December 31, 2018 $ 65,084 $ 152,294 $ 252,941 $ 246,769 $ 717,088 June 30, 2019 $ 162,219 $ 142,555 $ 222,506 $ 267,084 $ 794,364 In February 2019 $135,000

Note 7 - Intangible Assets

Note 7 - Intangible Assets	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. Intangible assets Computer software Trademarks Total intangible assets Cost Balance at December 31, 2017 $ 5,143 $ 16,236 $ 21,379 Additions - - - Balance at December 31, 2018 5,143 16,236 21,379 Additions - - - Balance at June 30, 2019 5,143 16,236 21,379 Accumulated amortization Balance at December 31, 2017 4,143 2,095 6,238 Amortization 1,000 1,083 2,083 Balance at December 31, 2018 5,143 3,178 8,321 Amortization - 537 537 Balance at June 30, 2019 5,143 3,715 8,858 Net book value as at: December 31, 2018 $ - $ 13,058 $ 13,058 June 30, 2019 $ - $ 12,521 $ 12,521

Note 8 - Leases

Note 8 - Leases	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases As discussed in Note 3, 842 January 1, 2019. two $1,613,038 The Company amortizes the asset on a straight-line basis and records the expense in the consolidated statement of operations and comprehensive loss. During the three six June 30, 2019, $127,345 $254,690 2018 nil

Note 9 - Loan Arrangements

Note 9 - Loan Arrangements	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	9. Loan arrangements On October 17, 2017, may $5,000,000, five 5 may one $250,000 one not two may fourteen 14% June 30, 2019, no

Note 10 - Preferred Stock

Note 10 - Preferred Stock	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred stock The Company is authorized to issue 20 1 $1,000,000. 1 not not 1 not 9 9 1 1 9 1 Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 1 1 In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which our shareholders do not 50% may third 1 1 1 5.0 9.0 1 Issued and outstanding preferred stock: Number of preferred Preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing (i) 12 11,962,811 Balance at June 30, 2019 12 $ 11,962,811 (i) On May 9, 2019, $12,000,000 1 $1,000,000 1 $5,000,000 May 9, 2019 $7,000,000 June 7, 2019. $37,189

Note 11 - Common Stock

Note 11 - Common Stock	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common stock The Company is authorized to issue an unlimited number of common shares, all without par value. Issued and outstanding common stock: Number of common Common stock stock amount Balance at December 31, 2017 90,225,869 $ 18,244,659 Stock issuance for services 641,717 1,238,513 Stock issued due to exercise of options 1,781,996 1,796,262 Stock issuance for financing, net of costs 1,861,627 3,978,690 Balance at June 30, 2018 94,511,209 $ 25,258,124 Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issued for services (i and ii) 707,236 792,104 Stock issued from financing (iii and iv) 9,337,529 6,690,922 Stock issued due to exercise of options 394,735 754,148 Balance at June 30, 2019 108,038,398 $ 38,647,822 (i) On January 14, 2019, $75,000 49,342 $55,263 $19,737 (ii) On January 14, 2019, 657,894 $1,000,000 third $736,841 (iii) On January 14, 2019, 2,815,789 $4,280,000 December 31, 2018.The $465 (iv) On March 28, 2019, 6,521,740 $3,000,000. $592,707 three March 31, 2019. $4,094 three June 30, 2019.

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock-based compensation During the three June 30, 2019, nil three June 30, 2018, 154,000 six June 30, 2019, 394,735 six June 30, 2018, 1,781,996 three June 30, 2019, nil six June 30, 2019, 5,995,000 one three six June 30, 2018, nil The continuity of stock options are as follows: Number of options Weighted avg exercise price (US$)(i) Balance at December 31, 2018 422,004 $ 1.95 Stock options granted January 10, 2019 5,995,000 1.52 Stock options expired February 24, 2019 (35,000 ) 1.12 Stock options exercised March 8, 2019 (164,473 ) 1.52 Stock options exercised March 15, 2019 (164,473 ) 1.52 Stock options exercised March 29, 2019 (65,789 ) 1.52 Stock options expired May 23, 2019 (10,000 ) 1.52 Stock options expired June 16, 2019 (40,000 ) 1.52 Balance at June 30, 2019 5,937,269 $ 1.56 (i) December 31, 2018, $2.65. As at June 30, 2019, Grant date Exercise price (US$) Number of options issued and outstanding Number of vested options outstanding Weighted avg remaining life (years) August 14, 2017 $ 2.16 387,004 387,004 0.12 January 10, 2019 $ 1.52 5,550,265 5,550,265 1.53 The fair value of options granted during the three six June 30, 2019 January 10, 2019 Volatility 68% Risk-free interest rate 2.56% Expected life 2 years Dividend yield 0% Common share price $1.23 Strike price $1.52 Forfeiture rate nil The Company recorded nil three June 30, 2019 ( three June 30, 2018 - $1,597 $2,341,104 six June 30, 2019 ( six June 30, 2018 - $7,288 nil three June 30, 2019. $600,000 $154,148 six June 30, 2019. $30,522 $6,517 154,000 three June 30, 2018. $1,438,308 $357,954 1,781,996 six June 30, 2018. The Company has estimated its stock option forfeitures to be nil three six June 30, 2019 ( three six June 30, 2018 - nil

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and contingencies On October 1, 2018, one not 842 one 2019 $ 5,940 Total $ 5,940 On November 26, 2018, • 1st September 12, 2019, ° $3,000,000 ° $1,500,000 $1.95 • 2nd February 19, 2020 - $2,000,000 As at June 30, 2019, On May 10, 2018, • 1st $3,500,000 • 2nd $3,500,000 10 As at June 30, 2019,

Note 14 - Financial Instruments

Note 14 - Financial Instruments	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	14. Financial instruments (a) Fair values The Company follows ASC topic 820, 820 820 three three three Level 1 Level 2 1 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is not (c) Foreign exchange risk The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 10% $0.1 (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at June 30, 2019 December 31, 2018: June 30, 2019 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,796,803 - - - - 1,796,803 1,796,803 - - - - 1,796,803 December 31, 2018 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,376,519 - - - - 2,376,519 2,376,519 - - - - 2,376,519

Note 15 - Segmented Information

Note 15 - Segmented Information	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. Segmented information The Company's operations comprise a single June 30, December 31, 2019 2018 $ $ Total assets Canada 711,142 383,567 US 8,768,265 5,649,952 Total US property and equipment 794,364 717,088 Tota US right-of-use asset 1,358,348 - 2,152,712 717,088

Note 16 - Schedule of Expenses

Note 16 - Schedule of Expenses	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Operating Expenses [Text Block]	16. Schedule of expenses For the three months ended June 30, For the three months ended June 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 232,929 $ - $ 643,519 $ 174,067 $ - $ 859,268 Contracted expenditures 557,719 - - 438,689 - - Marketing and investor relations - - 78,905 - - 41,962 Travel and accommodation 2,727 - 62,473 3,547 - 70,463 Insurance 26,994 - 49,887 28,284 - 77,282 License fees 50,000 - - 1,738,513 - - Office 13,169 - 50,342 3,129 - 61,460 Consultants 89,094 211,520 - 52,073 336,455 - Regulatory 42,647 - 26,066 19,388 - 90,142 Rent - - 5,940 7,825 - 43,019 Supplies 46,228 - 4,314 69,105 - 4,894 Total $ 1,061,507 $ 211,520 $ 921,446 $ 2,534,620 $ 336,455 $ 1,248,490 For the six months ended June 30, For the six months ended June 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 449,791 $ - $ 3,573,022 $ 326,440 $ - $ 1,502,556 Contracted expenditures 1,812,566 - - 708,212 - - Marketing and investor relations - - 131,415 - - 123,155 Travel and accommodation 12,776 - 119,737 5,336 - 191,868 Insurance 56,905 - 113,338 44,244 - 157,743 License fees 5,936,841 - - 1,738,513 - - Office 19,597 - 136,489 34,646 - 138,406 Consultants 148,880 950,914 - 89,189 708,402 - Regulatory 63,645 - 50,170 38,175 - 193,700 Rent - - 11,880 15,652 - 86,038 Supplies 91,881 - 16,658 134,554 - 15,196 Total $ 8,592,882 $ 950,914 $ 4,152,709 $ 3,134,961 $ 708,402 $ 2,408,662

Note 17 - Capital Risk Manageme

Note 17 - Capital Risk Management	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Capital Risk Management [Text Block]	17. Capital risk management The capital of the Company includes equity, which is comprised of issued common capital stock, additional paid-in capital, and accumulated deficit. The Company's objective when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders, and other stakeholders and to maintain a strong capital base to support the Company's core activities.

Note 18 - Loss Per Share

Note 18 - Loss Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	18. Loss per share For the three months ended June 30, For the six months ended June 30, 2019 2018 2019 2018 Numerator Net loss for the period $ 2,404,427 $ 4,144,398 $ 14,081,337 $ 6,315,727 Denominator Weighted average shares - basic 108,038,398 92,527,470 104,528,705 91,527,862 Stock options - - - - Denominator for diluted loss per share 108,038,398 92,527,470 104,528,705 91,527,862 Loss per share - basic and diluted $ (0.02 ) $ (0.04 ) $ (0.13 ) $ (0.07 ) For the above-mentioned periods, the Company had securities outstanding which could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive.

Note 19 - Related Party Transac

Note 19 - Related Party Transactions and Key Management Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	19. Related party transactions and key management compensation Key management personnel are comprised of the Company’s directors and executive officers. In addition to their salaries, key management personnel also receive share-based compensation. Key management personnel compensation is as follows: For the three months ended For the six months ended 2019 2018 2019 2018 Salaries and benefits, including bonuses $ 375,177 $ 381,046 $ 635,898 $ 721,665 Stock-based compensation - - 1,644,325 - Total $ 375,177 $ 381,046 $ 2,280,223 $ 721,665

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; deferred income taxes and forecasting future cash flows for assessing the going concern assumption.
Basis of Measurement [Policy Text Block]	Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.
Functional and Reporting Currencies [Policy Text Block]	Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements.
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730.
Share Issue Costs [Policy Text Block]	Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not three six June 30, 2019
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss The Company follows ASC topic 220. no
New Accounting Pronouncements, Policy [Policy Text Block]	Recently adopted accounting pronouncements In February 2016, No. 2016 02, 842 12 842 December 15, 2018. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. The Company adopted the new standard with an initial application date of January 1, 2019 not not January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permits the Company not not not

Note 5 - Prepaid Expenses and_2

Note 5 - Prepaid Expenses and Deposits (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Prepaid Expenses and Deposits [Table Text Block]	June 30, December 31, 2019 2018 Prepaid rent (i) $ - $ 1,613,038 Deposits (ii) 1,224,180 1,596,104 Prepaid FDA fees 62,995 - Prepaid marketing (iii) 41,218 37,465 Prepaid insurance (iii) 780 33,372 Other (iv) 67,303 29,470 Total $ 1,396,476 $ 3,309,449

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2017 $ 151,155 $ 76,058 $ 245,729 $ 36,957 $ 509,899 Additions 18,847 105,821 246,375 256,954 627,997 Disposals - - (139,467 ) (10,936 ) (150,403 ) Balance at December 31, 2018 170,002 181,879 352,637 282,975 987,493 Additions 137,126 3,414 3,350 65,673 209,563 Disposals (2,210 ) - - - (2,210 ) Balance at June 30, 2019 304,918 185,293 355,987 348,648 1,194,846 Accumulated depreciation Balance at December 31, 2017 42,802 11,845 74,875 9,220 138,742 Depreciation 62,116 17,740 86,368 37,460 203,684 Disposals - - (61,547 ) (10,474 ) (72,021 ) Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 38,683 13,153 33,785 45,358 130,979 Disposals (902 ) - - - (902 ) Balance at June 30, 2019 142,699 42,738 133,481 81,564 400,482 Net book value as at: December 31, 2018 $ 65,084 $ 152,294 $ 252,941 $ 246,769 $ 717,088 June 30, 2019 $ 162,219 $ 142,555 $ 222,506 $ 267,084 $ 794,364

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Computer software Trademarks Total intangible assets Cost Balance at December 31, 2017 $ 5,143 $ 16,236 $ 21,379 Additions - - - Balance at December 31, 2018 5,143 16,236 21,379 Additions - - - Balance at June 30, 2019 5,143 16,236 21,379 Accumulated amortization Balance at December 31, 2017 4,143 2,095 6,238 Amortization 1,000 1,083 2,083 Balance at December 31, 2018 5,143 3,178 8,321 Amortization - 537 537 Balance at June 30, 2019 5,143 3,715 8,858 Net book value as at: December 31, 2018 $ - $ 13,058 $ 13,058 June 30, 2019 $ - $ 12,521 $ 12,521

Note 10 - Preferred Stock (Tabl

Note 10 - Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Preferred Stock [Table Text Block]	Number of preferred Preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing (i) 12 11,962,811 Balance at June 30, 2019 12 $ 11,962,811

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Number of common Common stock stock amount Balance at December 31, 2017 90,225,869 $ 18,244,659 Stock issuance for services 641,717 1,238,513 Stock issued due to exercise of options 1,781,996 1,796,262 Stock issuance for financing, net of costs 1,861,627 3,978,690 Balance at June 30, 2018 94,511,209 $ 25,258,124 Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issued for services (i and ii) 707,236 792,104 Stock issued from financing (iii and iv) 9,337,529 6,690,922 Stock issued due to exercise of options 394,735 754,148 Balance at June 30, 2019 108,038,398 $ 38,647,822

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of options Weighted avg exercise price (US$)(i) Balance at December 31, 2018 422,004 $ 1.95 Stock options granted January 10, 2019 5,995,000 1.52 Stock options expired February 24, 2019 (35,000 ) 1.12 Stock options exercised March 8, 2019 (164,473 ) 1.52 Stock options exercised March 15, 2019 (164,473 ) 1.52 Stock options exercised March 29, 2019 (65,789 ) 1.52 Stock options expired May 23, 2019 (10,000 ) 1.52 Stock options expired June 16, 2019 (40,000 ) 1.52 Balance at June 30, 2019 5,937,269 $ 1.56
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Grant date Exercise price (US$) Number of options issued and outstanding Number of vested options outstanding Weighted avg remaining life (years) August 14, 2017 $ 2.16 387,004 387,004 0.12 January 10, 2019 $ 1.52 5,550,265 5,550,265 1.53
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	January 10, 2019 Volatility 68% Risk-free interest rate 2.56% Expected life 2 years Dividend yield 0% Common share price $1.23 Strike price $1.52 Forfeiture rate nil

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2019 $ 5,940 Total $ 5,940

Note 14 - Financial Instrumen_2

Note 14 - Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]	June 30, 2019 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,796,803 - - - - 1,796,803 1,796,803 - - - - 1,796,803 December 31, 2018 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,376,519 - - - - 2,376,519 2,376,519 - - - - 2,376,519

Note 15 - Segmented Informati_2

Note 15 - Segmented Information (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	June 30, December 31, 2019 2018 $ $ Total assets Canada 711,142 383,567 US 8,768,265 5,649,952 Total US property and equipment 794,364 717,088 Tota US right-of-use asset 1,358,348 - 2,152,712 717,088

Note 16 - Schedule of Expenses

Note 16 - Schedule of Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Operating Expenses [Table Text Block]	For the three months ended June 30, For the three months ended June 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 232,929 $ - $ 643,519 $ 174,067 $ - $ 859,268 Contracted expenditures 557,719 - - 438,689 - - Marketing and investor relations - - 78,905 - - 41,962 Travel and accommodation 2,727 - 62,473 3,547 - 70,463 Insurance 26,994 - 49,887 28,284 - 77,282 License fees 50,000 - - 1,738,513 - - Office 13,169 - 50,342 3,129 - 61,460 Consultants 89,094 211,520 - 52,073 336,455 - Regulatory 42,647 - 26,066 19,388 - 90,142 Rent - - 5,940 7,825 - 43,019 Supplies 46,228 - 4,314 69,105 - 4,894 Total $ 1,061,507 $ 211,520 $ 921,446 $ 2,534,620 $ 336,455 $ 1,248,490 For the six months ended June 30, For the six months ended June 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 449,791 $ - $ 3,573,022 $ 326,440 $ - $ 1,502,556 Contracted expenditures 1,812,566 - - 708,212 - - Marketing and investor relations - - 131,415 - - 123,155 Travel and accommodation 12,776 - 119,737 5,336 - 191,868 Insurance 56,905 - 113,338 44,244 - 157,743 License fees 5,936,841 - - 1,738,513 - - Office 19,597 - 136,489 34,646 - 138,406 Consultants 148,880 950,914 - 89,189 708,402 - Regulatory 63,645 - 50,170 38,175 - 193,700 Rent - - 11,880 15,652 - 86,038 Supplies 91,881 - 16,658 134,554 - 15,196 Total $ 8,592,882 $ 950,914 $ 4,152,709 $ 3,134,961 $ 708,402 $ 2,408,662

Note 18 - Loss Per Share (Table

Note 18 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months ended June 30, For the six months ended June 30, 2019 2018 2019 2018 Numerator Net loss for the period $ 2,404,427 $ 4,144,398 $ 14,081,337 $ 6,315,727 Denominator Weighted average shares - basic 108,038,398 92,527,470 104,528,705 91,527,862 Stock options - - - - Denominator for diluted loss per share 108,038,398 92,527,470 104,528,705 91,527,862 Loss per share - basic and diluted $ (0.02 ) $ (0.04 ) $ (0.13 ) $ (0.07 )

Note 19 - Related Party Trans_2

Note 19 - Related Party Transactions and Key Management Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Key Management Personnel Compensation [Table Text Block]	For the three months ended For the six months ended 2019 2018 2019 2018 Salaries and benefits, including bonuses $ 375,177 $ 381,046 $ 635,898 $ 721,665 Stock-based compensation - - 1,644,325 - Total $ 375,177 $ 381,046 $ 2,280,223 $ 721,665

Note 1 - Nature of Operations_2

Note 1 - Nature of Operations and Going Concern (Details Textual) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Retained Earnings (Accumulated Deficit), Ending Balance	$ (46,355,124)	$ (32,273,787)

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Other Comprehensive Income (Loss), Net of Tax, Total	$ 0

Note 5 - Prepaid Expenses and_3

Note 5 - Prepaid Expenses and Deposits (Details Textual)	Jul. 31, 2018USD ($)ft²	Jun. 30, 2019USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Payments for Rent	$ 1,269,073
Operating Lease, Right-of-Use Asset		$ 1,358,348	$ 1,613,038
Prepaid Rent				509,380
Deposits Assets, Current		$ 1,389,176		$ 1,867,034
Wickfield Phoenix LLC Office Space [Member]
Area of Real Estate Property | ft²	18,640

Note 5 - Prepaid Expenses and_4

Note 5 - Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Details) - USD ($)		Jun. 30, 2019	Dec. 31, 2018
Prepaid rent	[1]		$ 1,613,038
Deposits	[2]	1,224,180	1,596,104
Prepaid FDA fees		62,995
Prepaid marketing	[3]	41,218	37,465
Prepaid insurance	[3]	780	33,372
Other	[4]	67,303	29,470
Total		$ 1,396,476	$ 3,309,449
[1]	On July 31, 2018, the Company entered into an amended lease agreement with Wickfield Phoenix LLC for an additional 18,640 square feet of office space. The Company prepaid the full outstanding balance of $1,269,073. As of January 1, 2019 the balance of the prepaid rent, inclusive of the original and amended lease amounts was $1,613,038. In accordance with ASC 842, this amount was reclassified as a right-of-use asset in the consolidated balance sheet. As of December 31, 2018, the Company classified $509,380 as a current asset in the consolidated balance sheet;
[2]	Deposits include payments made to vendors in advance and are primarily associated with research activity, design fees for additional office space, and equipment purchases. As of June 30, 2019 and December 31, 2018, the Company classified $1,389,176 and $1,867,034 as a current asset in the consolidated balance sheet, respectively;
[3]	As of June 30, 2019 and December 31, 2018, all amounts were classified as a current asset in the consolidated balance sheet;
[4]	Other is comprised of subscription payments and software licensing. As of June 30, 2019 and December 31, 2018, the Company classified all amounts as a current asset in the consolidated balance sheet.

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual)	1 Months Ended
	Feb. 28, 2019USD ($)
Reclassificaiton From Prepaid Assets to Property, Plant and Equipment	$ 135,000

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Cost, Beginning Balance	$ 987,493	$ 509,899
Cost, Additions	209,563	627,997
Cost, Disposals	(2,210)	(150,403)
Cost, Ending Balance	1,194,846	987,493
Accumulated Depreciation, Beginning Balance	270,405	138,742
Accumulated Depreciation, Depreciation	130,979	203,684
Accumulated Depreciation, Disposals	(902)	(72,021)
Accumulated Depreciation, Ending Balance	400,482	270,405
Net Book Value	794,364	717,088
Computer Equipment [Member]
Cost, Beginning Balance	170,002	151,155
Cost, Additions	137,126	18,847
Cost, Disposals	(2,210)
Cost, Ending Balance	304,918	170,002
Accumulated Depreciation, Beginning Balance	104,918	42,802
Accumulated Depreciation, Depreciation	38,683	62,116
Accumulated Depreciation, Disposals	(902)
Accumulated Depreciation, Ending Balance	142,699	104,918
Net Book Value	162,219	65,084
Furniture and Fixtures [Member]
Cost, Beginning Balance	181,879	76,058
Cost, Additions	3,414	105,821
Cost, Disposals
Cost, Ending Balance	185,293	181,879
Accumulated Depreciation, Beginning Balance	29,585	11,845
Accumulated Depreciation, Depreciation	13,153	17,740
Accumulated Depreciation, Disposals
Accumulated Depreciation, Ending Balance	42,738	29,585
Net Book Value	142,555	152,294
Laboratory Equipment [Member]
Cost, Beginning Balance	352,637	245,729
Cost, Additions	3,350	246,375
Cost, Disposals		(139,467)
Cost, Ending Balance	355,987	352,637
Accumulated Depreciation, Beginning Balance	99,696	74,875
Accumulated Depreciation, Depreciation	33,785	86,368
Accumulated Depreciation, Disposals		(61,547)
Accumulated Depreciation, Ending Balance	133,481	99,696
Net Book Value	222,506	252,941
Leasehold Improvements [Member]
Cost, Beginning Balance	282,975	36,957
Cost, Additions	65,673	256,954
Cost, Disposals		(10,936)
Cost, Ending Balance	348,648	282,975
Accumulated Depreciation, Beginning Balance	36,206	9,220
Accumulated Depreciation, Depreciation	45,358	37,460
Accumulated Depreciation, Disposals		(10,474)
Accumulated Depreciation, Ending Balance	81,564	36,206
Net Book Value	$ 267,084	$ 246,769

Note 7 - Intangible Assets - Fi

Note 7 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Cost, Beginning Balance			$ 21,379	$ 21,379	$ 21,379
Cost, Additions
Cost, Ending Balance	$ 21,379		21,379		21,379
Accumulated Amortization, Beginning Balance			8,321	6,238	6,238
Accumulated Amortization, Amortization	270	$ 693	537	1,379	2,083
Accumulated Amortization, Ending Balance	8,858		8,858		8,321
Net Book Value	12,521		12,521		13,058
Computer Software, Intangible Asset [Member]
Cost, Beginning Balance			5,143	5,143	5,143
Cost, Additions
Cost, Ending Balance	5,143		5,143		5,143
Accumulated Amortization, Beginning Balance			5,143	4,143	4,143
Accumulated Amortization, Amortization					1,000
Accumulated Amortization, Ending Balance	5,143		5,143		5,143
Net Book Value
Trademarks [Member]
Cost, Beginning Balance			16,236	16,236	16,236
Cost, Additions
Cost, Ending Balance	16,236		16,236		16,236
Accumulated Amortization, Beginning Balance			3,178	$ 2,095	2,095
Accumulated Amortization, Amortization			537		1,083
Accumulated Amortization, Ending Balance	3,715		3,715		3,178
Net Book Value	$ 12,521		$ 12,521		$ 13,058

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	Jan. 01, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Number of Lease Agreements		2		2
Operating Lease, Right-of-Use Asset, Amortization		$ 127,345		$ 254,690		$ 0
Accounting Standards Update 2016-02 [Member]
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 1,613,038

Note 9 - Loan Arrangements (Det

Note 9 - Loan Arrangements (Details Textual) - Loan Arrangement With Shareholder [Member] - USD ($)	Oct. 17, 2017	Jun. 30, 2019
Debt Agreement, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term	5 years
Debt Agreement, Minimum Borrowing Per Advances	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Long-term Debt, Total		$ 0

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Jun. 07, 2019	May 09, 2019	Jan. 14, 2019	Jun. 07, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 10, 2019	Dec. 31, 2018
Preferred Stock, Shares Authorized					20		20			0
Share Price									$ 1.23
Proceeds from Issuance of Preferred Stock and Preference Stock					$ 12,000,000		$ 12,000,000
Payments of Stock Issuance Costs					$ 33,095	$ 23,806	$ 626,267	$ 23,806
Private Placement [Member]
Payments of Stock Issuance Costs			$ 465
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized					20		20
Preferred Stock, Stated Value Per Share					$ 1,000,000		$ 1,000,000
Series 1 Preferred Shares [Member] | Private Placement [Member]
Preferred Stock, Value, Subscriptions		$ 12,000,000
Share Price		$ 1,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 7,000,000	$ 5,000,000
Payments of Stock Issuance Costs				$ 37,189

Note 10 - Preferred Stock - Iss

Note 10 - Preferred Stock - Issued and Outstanding Preferred Stock (Details)	6 Months Ended
	Jun. 30, 2019USD ($)shares
Balance, number (in shares) | shares	0
Balance, amount | $
Balance, number (in shares) | shares	12
Balance, amount | $	$ 11,962,811
Series 1 Preferred Shares [Member]
Balance, number (in shares) | shares
Balance, amount | $
Stock issued from financing, number (in shares) | shares	12	[1]
Stock issued from financing, amount | $	$ 11,962,811	[1]
Balance, number (in shares) | shares	12
Balance, amount | $	$ 11,962,811
[1]	On May 9, 2019, the Company entered into subscription agreements to sell $12,000,000 of its Series 1 Preferred Shares to an accredited investor in a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share; $5,000,000 of the purchase price was paid on May 9, 2019 and the remaining $7,000,000 was paid on June 7, 2019. The Company recorded $37,189 of share issuance costs as an offset to preferred stock.

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual) - USD ($)	Mar. 28, 2019	Jan. 14, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Gain (Loss) on Settlement of Liabilities						$ 19,737
Research and Development Expense, Total				1,061,507	2,534,620	8,592,882	3,134,961
Payments of Stock Issuance Costs				33,095	23,806	626,267	23,806
Proceeds from Issuance of Common Stock					$ 4,002,496	$ 3,000,000	$ 4,002,496
Increase (Decrease) in Stock Issuance Costs				$ (4,094)
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		2,815,789
Proceeds from Issuance of Private Placement			$ 4,280,000
Payments of Stock Issuance Costs		$ 465
Public Offering [Member]
Stock Issued During Period, Shares, New Issues	6,521,740
Payments of Stock Issuance Costs	$ 592,707
Proceeds from Issuance of Common Stock	$ 3,000,000
One Creditor [Member]
Debt Conversion, Converted Instrument, Amount		$ 75,000
Common Stock, Number of Shares, Issued		49,342
Common Stock, Value, Issued		$ 55,263
Gain (Loss) on Settlement of Liabilities		$ 19,737
Celsee [Member]
Common Stock, Number of Shares, Issued		657,894
Common Stock, Value, Issued		$ 1,000,000
Research and Development Expense, Total		$ 736,841

Note 11 - Common Stock - Issued

Note 11 - Common Stock - Issued and Outstanding Common Shares (Details) - USD ($)		Mar. 29, 2019	Mar. 15, 2019	Mar. 08, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019		Jun. 30, 2018
Number of common shares (in shares)							97,598,898
Stock issuance for services (in shares)									641,717
Stock issuance for services							$ 792,104		$ 1,238,513
Stock issued due to exercise of options (in shares)		65,789	164,473	164,473	0	154,000	394,735		1,781,996
Stock issued due to exercise of options							$ 600,000		$ 1,438,308
Stock issuance for financing, net of costs (in shares)									1,861,627
Stock issuance for financing, net of costs							$ 14,373,733		$ 3,978,690
Number of common shares (in shares)					108,038,398		108,038,398
Common Stock [Member]
Number of common shares (in shares)							97,598,898		90,225,869
Capital stock							$ 30,410,648		$ 18,244,659
Stock issuance for services (in shares)							707,236	[1],[2]	641,717
Stock issuance for services							$ 792,104	[1],[2]	$ 1,238,513
Stock issued due to exercise of options (in shares)							394,735		1,781,996
Stock issued due to exercise of options							$ 754,148		$ 1,796,262
Stock issuance for financing, net of costs (in shares)	[3],[4]						9,337,529
Stock issuance for financing, net of costs							$ 6,690,922	[3],[4]	$ 3,978,690
Number of common shares (in shares)					108,038,398	94,511,209	108,038,398		94,511,209
Capital stock					$ 38,647,822	$ 25,258,124	$ 38,647,822		$ 25,258,124
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance;
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities;
[3]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018.The Company recorded $465 of share issuance costs as an offset to common stock;
[4]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded $592,707 of share issuance costs as an offset to common stock in the three month period ended March 31, 2019. A decrease of $4,094 in share issuance costs was recorded as an offset to common stock in the three month period ended June 30, 2019.

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) $ / shares in Units, xbrli-pure in Thousands	Mar. 29, 2019shares	Mar. 15, 2019shares	Mar. 08, 2019shares	Jan. 10, 2019shares	Jun. 30, 2019USD ($)$ / sharesshares		Jun. 30, 2018USD ($)shares	Jun. 30, 2019USD ($)$ / sharesshares		Jun. 30, 2018USD ($)shares	Dec. 31, 2018$ / shares	Dec. 31, 2018$ / shares	[1]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares	65,789	164,473	164,473		0		154,000	394,735		1,781,996
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares				5,995,000	0		0	5,995,000		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | (per share)					$ 1.56	[1]		$ 1.56	[1]		$ 2.65	$ 1.95
Share-based Payment Arrangement, Expense					$ 0		$ 1,597	$ 2,341,104		$ 7,288
Proceeds from Stock Options Exercised					$ 0		$ 30,522	600,000		1,438,308
Stock Issued During Period, Value, Stock Options Exercised								$ 600,000		$ 1,438,308
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate					0.00%		0.00%	0.00%		0.00%
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised							$ (6,517)	$ (154,148)		$ (357,954)
[1]	As of the year ended December 31, 2018, the weighted average exercised price in CDN$ was $2.65.

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Issuance of Stock Options (Details)		Jun. 16, 2019$ / sharesshares	May 23, 2019$ / sharesshares	Mar. 29, 2019$ / sharesshares	Mar. 15, 2019$ / sharesshares	Mar. 08, 2019$ / sharesshares	Feb. 24, 2019$ / sharesshares		Jan. 10, 2019$ / sharesshares	Jun. 30, 2019$ / sharesshares		Jun. 30, 2018shares	Jun. 30, 2019$ / sharesshares		Jun. 30, 2018shares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2018$ / sharesshares
Number of Options, Options Outstanding (in shares)										5,937,269			5,937,269			422,004	422,004
Weighted Avg Exercise Price, Options Outstanding (in dollars per share) | (per share)										$ 1.56	[1]		$ 1.56	[1]		$ 2.65	$ 1.95	[1]
Number of Options, Options Granted (in shares)									5,995,000	0		0	5,995,000		0
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]								$ 1.52
Number of Options, Options Expired (in shares)		(40,000)	(10,000)				(35,000)
Weighted Avg Exercise Price, Options Expired (in dollars per share) | $ / shares		$ 1.52	$ 1.52				$ 1.12	[1]
Number of Options, Options Exercised (in shares)				(65,789)	(164,473)	(164,473)				0		(154,000)	(394,735)		(1,781,996)
Weighted Avg Exercise Price, Options Exercised (in dollars per share) | $ / shares	[1]			$ 1.52	$ 1.52	$ 1.52
[1]	As of the year ended December 31, 2018, the weighted average exercised price in CDN$ was $2.65.

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares		Jan. 10, 2019	Jun. 30, 2019	Dec. 31, 2018
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]	$ 1.52
Number of Options, Options Outstanding (in shares)			5,937,269	422,004
Options 1 [Member] | August 14, 2017 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)			$ 2.16
Number of Options, Options Outstanding (in shares)			387,004
Number of Vested Options (in shares)			387,004
Weighted Avg Remaining Life (Year)			43 days
Options 1 [Member] | January 10, 2019 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)			$ 1.52
Number of Options, Options Outstanding (in shares)			5,550,265
Number of Vested Options (in shares)			5,550,265
Weighted Avg Remaining Life (Year)			1 year 193 days
[1]	As of the year ended December 31, 2018, the weighted average exercised price in CDN$ was $2.65.

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details)	Jan. 10, 2019$ / shares
Volatility	68.00%
Risk-free interest rate	2.56%
Expected life (Year)	2 years
Dividend yield	0.00%
Common share price (in dollars per share)	$ 1.23
Strike price (in dollars per share)	$ 1.52
Forfeiture rate

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 26, 2018	May 10, 2018
Qorvo Biotechnologies, LLC [Member]
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Cash Only	$ 3,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Cash Portion	1,500,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Equity Portion	1,950,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Fourth Payment, Cash Only	$ 2,000,000
Seraph Biosciences, Inc. [Member]
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash		$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity		$ 3,500,000

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies - Future Annual Lease Payments (Details)	Jun. 30, 2019USD ($)
2019	$ 5,940
Total	$ 5,940

Note 14 - Financial Instrumen_3

Note 14 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accounts Payable and Accrued Liabilities, Maturity Less Than 3 Months	$ 1,796,803	$ 2,376,519
Accounts payable and accrued liabilities, Maturity 3 to 6 Months
Accounts payable and accrued liabilities, Maturity 6 to 9 Months
Accounts payable and accrued liabilities, Maturity 9 to 12 Months
Accounts payable and accrued liabilities, Maturity Greater Than 1 Year
Accounts payable and accrued liabilities	1,796,803	2,376,519
Contractual Financial Liabilities, Maturity Less Than 3 Months	1,796,803	2,376,519
Contractual Financial Liabilities, , Maturity 3 to 6 Months
Contractual Financial Liabilities, Maturity 6 to 9 Months
Contractual Financial Liabilities, Maturity 9 to 12 Months
Contractual Financial Liabilities, Maturity Greater Than 1 Year
Contractual Financial Liabilities	1,796,803	2,376,519
Accounts payable and accrued liabilities	$ 1,796,803	$ 2,376,519

Note 15 - Segmented Informati_3

Note 15 - Segmented Information (Details Textual)	6 Months Ended
	Jun. 30, 2019
Number of Reportable Segments	1

Note 15 - Segmented Informati_4

Note 15 - Segmented Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Assets	$ 9,479,407		$ 6,033,519
Total US property and equipment	794,364		717,088
Tota US right-of-use asset	1,358,348	$ 1,613,038
CANADA
Assets	711,142		383,567
UNITED STATES
Assets	8,768,265		5,649,952
Total US property and equipment	794,364		717,088
Tota US right-of-use asset	1,358,348
	$ 2,152,712		$ 717,088

Note 16 - Schedule of Expense_2

Note 16 - Schedule of Expenses - Schedule of Expenses (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Research and development	$ 1,061,507	$ 2,534,620	$ 8,592,882	$ 3,134,961
Professional fees	211,520	336,455	950,914	708,402
General and administrative	921,446	1,248,490	4,152,709	2,408,662
Salaries, Bonus and Benefits [Member]
Research and development	232,929	174,067	449,791	326,440
Professional fees
General and administrative	643,519	859,268	3,573,022	1,502,556
Contracted Expenditures [Member]
Research and development	557,719	438,689	1,812,566	708,212
Professional fees
General and administrative
Marketing and Investor Relations [Member]
Research and development
Professional fees
General and administrative	78,905	41,962	131,415	123,155
Travel and Accommodation [Member]
Research and development	2,727	3,547	12,776	5,336
Professional fees
General and administrative	62,473	70,463	119,737	191,868
Insurance [Member]
Research and development	26,994	28,284	56,905	44,244
Professional fees
General and administrative	49,887	77,282	113,338	157,743
License Fees [Member]
Research and development	50,000	1,738,513	5,936,841	1,738,513
Professional fees
General and administrative
Office [Member]
Research and development	13,169	3,129	19,597	34,646
Professional fees
General and administrative	50,342	61,460	136,489	138,406
Consultant [Member]
Research and development	89,094	52,073	148,880	89,189
Professional fees	211,520	336,455	950,914	708,402
General and administrative
Regulatory [Member]
Research and development	42,647	19,388	63,645	38,175
Professional fees
General and administrative	26,066	90,142	50,170	193,700
Amortization, Right-of-use Asset [Member]
Research and development		7,825		15,652
Professional fees
General and administrative	5,940	43,019	11,880	86,038
Supplies [Member]
Research and development	46,228	69,105	91,881	134,554
Professional fees
General and administrative	$ 4,314	$ 4,894	$ 16,658	$ 15,196

Note 18 - Loss Per Share - Loss

Note 18 - Loss Per Share - Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net loss for the period	$ 2,404,427	$ 4,144,398	$ 14,081,337	$ 6,315,727
Weighted average shares - basic (in shares)	108,038,398	92,527,470	104,528,705	91,527,862
Stock options (in shares)
Denominator for diluted loss per share (in shares)	108,038,398	92,527,470	104,528,705	91,527,862
Loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.04)	$ (0.13)	$ (0.07)

Note 19 - Related Party Trans_3

Note 19 - Related Party Transactions and Key Management Compensation - Key Management Personnel Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock-based compensation	$ 0	$ 1,597	$ 2,341,104	$ 7,288
Director and Executive Officers [Member]
Salaries and benefits, including bonuses	375,177	381,046	635,898	721,665
Stock-based compensation			1,644,325
Total	$ 375,177	$ 381,046	$ 2,280,223	$ 721,665